Tackling pancreatic cancer with metronomic chemotherapy

摘要: Pancreatic tumours, the majority of which arise from exocrine pancreas, have recently shown an increasing incidence in western countries. Over past few years more and new selective molecules directed against specific cellular targets become available for cancer therapy, leading to significant improvements. However, despite such advances prognosis pancreatic remains disappointing. Metronomic chemotherapy (MCT), consists administration continuous, low-dose anticancer drugs, has demonstrated ability suppress tumour growth. Thus, it may provide additional therapeutic opportunity counteracting progression tumour. Here we discuss evidence arising preclinical clinical studies regarding use MCT cancer. Good results generally been achieved studies, particularly when was combined with standard dose or antinflammatory, antiangiogenic immunostimolatory agents. The experiences, mainly refer retrospective data, reported good tolerability though mild activity metronomic schedules. Further are therefore awaited confirm both findings preliminary data.